• Twist Bioscience President and COO Patrick John Finn cut his stake to 214,678 shares via option exercise and same-day sales on Aug. 18.
• He exercised 23,355 stock options at USD 67.85, then sold 78,355 shares at weighted-average prices from USD 115.9 to USD 122.58.
• The filing shows the transactions were executed under a Rule 10b5-1 trading plan adopted May 18, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-010645), on August 20, 2026, and is solely responsible for the information contained therein.